Until the commercial viability of their products have been determined... any search for 'value' makes little sense here.
If they are in fact having troubles getting people to participate in their trials (even with the success in Europe) then the potential for success is overshadowed by the lack of interest which diminishes the value here substantially. How small is the market for this therapy if no one wants to get involved?
As for a reverse merger... I could get behind that on a more senior exchange but here? What company would want that? Not a good one.
Share price is not a true measure of a company's value.
With a quiet CEO, a lack of funding opportunities that caused a 350-1 RS which dropped it this low means no serious investors were willing to pay any more, and no visibility of why this dumping is happening or what the financial benefit is to the company... dangerous time to be buying here.
News 
Market Data 
Discover 
AI
